focus -WSS

focus

author：comprehensive 2025-10-01 12:35:50 - browse：564

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Can sheer will power keep patients alive in their dying hours?

hotspot

WSS

What Henrietta Lacks's story taught me about my role as a doctor

Hospitals owned by private equity see complications spike 25%

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Violet CEO on training clinicians to promote more inclusive care

Three trends to watch in biotech in 2024

Prime Medicine, Myeloid Therapeutics clash over genome

focus

focus

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Clinic falsely told dozens they had Alzheimer's, suits say

State Dept. review finds Biden bears some blame for Afghanistan failures

Inside the culture of fear in the White House science office of Eric Lander

Psychedelics group wrestles with new pharma identity

How to protect coverage of PrEP

How to save PrEP access — and even expand it

Violet CEO on training clinicians to promote more inclusive care

The high cost of giving birth even with insurance

HCA sued by state AG for quality issues at Mission Health

knowledge

Clinic falsely told dozens they had Alzheimer's, suits say

Violet CEO on training clinicians to promote more inclusive care

Hospitals owned by private equity see complications spike 25%

Why health records don't always know when patients are dead

Keeping primary care docs in field isn't impossible, says AAFP CEO

Readout Newsletter: The latest on Moderna, Apellis, and Merck

entertainment

hotspot

explore

explore